TiGenix announces closing of NASDAQ IPO
(Thomson Reuters ONE) -
PRESS RELEASE
TiGenix announces closing of NASDAQ IPO
Leuven (BELGIUM) - December 20, 2016, 16:00h CET - TiGenix NV (Euronext Brussels
& NASDAQ: TIG; "TiGenix"), an advanced biopharmaceutical company focused on
developing and commercializing novel therapeutics from its proprietary platforms
of allogeneic expanded stem cells, announced today the closing of its initial
public offering in the United States (the "Offering") totalling $35.65 million
gross proceeds from the sale of 2,300,000 American Depository Shares ("ADSs"),
representing 46,000,000 ordinary shares, at a price to the public of $15.50 per
ADS.
In connection with the Offering, the underwriters have a 30-day option to
purchase up to an additional 345,000 ADSs, representing 6,900,000 ordinary
shares, to cover over-allotments, if any.
Each of the ADSs offered represents the right to receive twenty (20) ordinary
shares.
TiGenix's ordinary shares are listed on Euronext Brussels under the symbol
"TIG". The ADSs are listed on the NASDAQ Global Select Market under the symbol
"TIG".
BofA Merrill Lynch and Cowen and Company, LLC acted as joint book-running
managers, Canaccord Genuity acted as lead manager and BTIG acted as co-manager
for the Offering.
A registration statement relating to these securities was declared effective by
the U.S. Securities and Exchange Commission on December 14, 2016.
Copies of the final prospectus for this Offering can be obtained from BofA
Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC
28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests(at)baml.com
and from Cowen and Company LLC, c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at
(631) 274-2806 or by fax at (631) 254-7140.
This press release is for information purposes only and does not constitute, and
should not be construed as, an offer to sell or the solicitation of an offer to
buy or subscribe to any securities of TiGenix, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make such offer,
solicitation or sale. This press release is not for publication or distribution,
directly or indirectly, in or into any state or jurisdiction into which doing so
would be unlawful.
For more information, please contact:
TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels & NASDAQ: TIG) is an advanced biopharmaceutical
company focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Our
lead product candidate from the adipose-derived stem cell technology platform is
Cx601, which is in registration with the European Medicines Agency for the
treatment of complex perianal fistulas in Crohn's disease patients. Our adipose-
derived stem cell product candidate Cx611 has completed a Phase I sepsis
challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July
31, 2015, TiGenix acquired Coretherapix, whose lead cellular product candidate,
AlloCSC-01, is currently in a Phase II clinical trial in Acute Myocardial
Infarction (AMI). In addition, the second product candidate from the cardiac
stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being
developed in a chronic indication. On July 4, 2016, TiGenix entered into a
licensing agreement with Takeda, a large pharmaceutical company active in
gastroenterology, under which Takeda acquired the exclusive right to
commercialize Cx601 for complex perianal fistulas outside the United States.
TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid
(Spain).
Forward-looking information
This press release may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in which
it operates. Certain of these statements, forecasts and estimates can be
recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that are
not historical facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may not
prove to be correct. Actual events are difficult to predict and may depend upon
factors that are beyond TiGenix's control. Therefore, actual results, the
financial condition, performance or achievements of TiGenix, or industry
results, may turn out to be materially different from any future results,
performance or achievements expressed or implied by such statements, forecasts
and estimates. Given these uncertainties, no representations are made as to the
accuracy or fairness of such forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and estimates only
speak as of the date of the publication of this press release. TiGenix disclaims
any obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in TiGenix's expectations with regard thereto,
or any change in events, conditions or circumstances on which any such
statement, forecast or estimate is based, except to the extent required by
applicable law.
IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or
is intended to, permit a public offering in any country or jurisdiction, other
than the United States, where any such action is required, including in Belgium.
Belgian investors, other than qualified investors within the meaning of the
Belgian Act of 16 June 2006 on the public offering of securities and the
admission of securities to be traded on a regulated market (the "Belgian
Prospectus Act"), will not be eligible to participate in the offering (whether
in Belgium or elsewhere). The transaction to which this press release relates
will only be available to, and will be engaged in only with, in member states of
the European Economic Area, persons falling within the meaning of Article
2(1)(e) of the Prospectus Directive 2003/71/EC as amended by Directive
2010/73/EU, and in the United Kingdom, investment professionals falling within
article 19 (5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order"), persons falling within article 49 (2), (a)
to (d) of the Order and other persons to whom it may lawfully be communicated. A
prospectus will be prepared by the TiGenix in accordance with Article 20 of the
Belgian Prospectus Act for the purpose of having the new shares that will be
represented by the ADSs admitted to trading on Euronext Brussels.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.12.2016 - 16:00 Uhr
Sprache: Deutsch
News-ID 514107
Anzahl Zeichen: 8638
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix announces closing of NASDAQ IPO"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
